Cutera, Inc. Receives FDA Clearance for Its New Laser, Pearl, Using YSGG Technology

BRISBANE, Calif., March 28 /PRNewswire-FirstCall/ -- Cutera, Inc.(R) , a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, today announced FDA clearance for its new laser, Pearl, with proprietary YSGG technology. Pearl is cleared for the treatment of wrinkles and represents the first application of the 2790 nm wavelength for cosmetic dermatology.

During treatment, Pearl removes a portion of the epidermis with a controlled thermal effect. The thermal effect creates a natural protective dressing on the skin to minimize downtime during the restorative process.

"What differentiates Pearl from traditional resurfacing products is its ability to denature a controlled depth of epidermis with minimal immediate tissue removal at the skin's surface," said E. Victor Ross, MD, board-certified dermatologist at Scripps Medical Center in San Diego. "This is an important benefit for restoring the skin's structure and vitality."

"We chose the YSGG wavelength because our current and prospective customers want a more aggressive solution to complement our non-ablative, no-downtime procedures," said Cutera President and CEO, Kevin Connors. "By introducing Pearl, we are entering into an emerging aesthetic market segment currently estimated at approximately $150 million per year and projected to be growing in excess of 30% per year."

Pearl is available for sale immediately on Cutera's multi-application Xeo platform, as an upgrade to all existing customers, and as a standalone unit. Shipments are expected to commence in the summer.

Pearl will be featured at the following upcoming meetings: -- American Society for Laser Medicine and Surgery (ASLMS) April 11 - 15, 2007 in Grapevine, Texas Cutera Booth # 510 -- American Society for Aesthetic Plastic Surgery (ASAPS) April 19 - 24, 2007 in New York Cutera Booth # 153 About Cutera, Inc.

Brisbane, Calif.-based Cutera is a leading provider of laser and other light-based aesthetic systems to the professional aesthetic market. Since 1998, Cutera has been developing innovative, easy-to-use products that enable dermatologists, plastic surgeons, gynecologists, primary care physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the anticipated success of obtaining regulatory clearances, compiling effective clinical studies and making, marketing and selling new products are forward-looking statements within the meaning of the Safe Harbor. Forward-Looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Cutera's business and its financial results are detailed in its most recent 10-K and 10-Q as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT: Elizabeth Conrady of Cutera, Inc., +1-415-657-5503, oreconrady@cutera.com; or Fran Kelly of Rpr Marketing Communications,+1-212-317-1462, or fkelly@rprny.com, for Cutera, Inc.

Web site: http://www.cutera.com//